Ankylosing Spondylitis Market To Reach $11.08 Billion By 2033

Ankylosing Spondylitis Market Growth & Trends

The global ankylosing spondylitis market size is expected to reach USD 11.08 billion by 2030, registering a CAGR of 6.4% from 2025 to 2033, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province’s public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

 Request a free sample copy or view report summary: Ankylosing Spondylitis Market Report

Ankylosing Spondylitis Market Report Highlights

• The TNF Inhibitors segment dominated the market with the largest revenue share of 58.70% in 2024, driven by their strong efficacy in controlling inflammation and slowing ankylosing spondylitis progression.

• The hospital pharmacy segment dominated the market with the largest revenue share of 47.80% in 2024, which can be attributed to the high administration of biologics and infusion-based therapies in hospital settings.

• The retail pharmacy segment is projected to grow at the fastest CAGR of 7.9% over the forecast period, driven by increasing patient preference for convenient access to oral and self-injectable therapies.

• North America held the largest share of the ankylosing spondylitis market in 2024, accounting for 57.32% of global revenue, due to the widespread availability of advanced biologics and biosimilars.

Ankylosing Spondylitis Market Segmentation

Grand View Research has segmented the global ankylosing spondylitis market report based on drug class, distribution channel, and region:

Ankylosing Spondylitis Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

• Non-Steroidal Anti-Inflammatory Drug (NSAID)

• TNF Inhibitors

  • Humira

  • Simponi

  • Remicade

  • Enbrel

  • Cimzia

  • Other TNF Inhibitors

• Other Drug Classes

Ankylosing Spondylitis Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Hospital Pharmacy

• Retail Pharmacy

• Others

Ankylosing Spondylitis Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Ankylosing Spondylitis Market

• AbbiVie, Inc.

• Amgen, Inc.

• Pfizer, Inc.

• Johnson & Johnson, Inc.

• Novartis AG

• UCB, Inc.

• Eli Lilly and Company

• Merck & Co., Inc.

• Zydus Lifescience Ltd.

• Izana Bioscience